Giuliana Cighetti

Giuliana Cighetti

Auto-generated profile, based on publicly available information

Giuliana Cighetti

University of Milan

Research Focus & Metrics

Academic Career Length

50Years (1977-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 1978 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
CSCesare R. Sirtori
Cesare R. Sirtori
GFGuido Franceschini
Guido Franceschini
MGMarzia Galli-Kienle
Marzia Galli-Kienle
GCGiuliana Cighetti
Giuliana Cighetti
GGGianni Galli
Gianni Galli
FCFranco Conti
Franco Conti

7 March 2002 in European Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
GCG. Cighetti
G. Cighetti
LDLorena Duca
Lorena Duca
LBL. Bortone
L. Bortone
SSS. Sala
S. Sala
INIsabella Nava
Isabella Nava
MCMaria Domenica Cappellini
Maria Domenica Cappellini

1 January 1999 in Analytical Biochemistry
Verified
Journal Article
Closed access
GCGiuliana Cighetti
Giuliana Cighetti
SDSandra Debiasi
Sandra Debiasi
Rita ParoniRita Paroni
Rita Paroni
PAPietro Allevi
Pietro Allevi

1 September 2001 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
Rita ParoniRita Paroni
Rita Paroni
ASAndrea Salonia
Andrea Salonia
ALAvigdor Lev
Avigdor Lev
LPLuigi Filippo Da Pozzo
Luigi Filippo Da Pozzo
GCGiuliana Cighetti
Giuliana Cighetti
RCRenzo Colombo
Renzo Colombo
Aims  To assess the effect of local hyperthermia on the systemic absorption of mitomycin C (MMC) during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma of the bladder, and to establish the likely safety of this procedure.Methods  Group 1 (n = 12) received 20 mg intravesical MMC plus local hyperthermia, group 2 (n = 13) 20 mg MMC alone, group 3 (n = 16) 40 mg MMC plus local hyperthermia and group 4 (n = 10) 40 mg MMC alone. Patients in groups 1, 2, and 4 underwent post‐tumour resection adjuvant treatment, whereas those in group 3 still had tumour present and were treated to eradicate it. Intravesical instillation lasted 60 min, with the solution (50 ml) being replaced after the first 30 min. Blood samples were taken before, and every 15 min during instillation. MMC concentrations in plasma and in urine were determined by h.p.l.c.Results  The highest MMC plasma concentration (67.9 ng ml−1) occurred in a patient in group 3. This value was well below the threshold concentration (400 ng ml−1) for myelosuppression. Local hyperthermia associated with the intravesical chemotherapy enhanced plasma MMC concentrations at 30, 45 and 60 min compared with chemotherapy alone (Group 1 vs 2, P ≤ 0.008). Systemic exposure to MMC was not significantly increased by doubling the intravesical dose when intravesical chemotherapy alone was administered. Patients in group 3 displayed the highest degree of MMC absorption and the greatest variability in pharmacokinetics between patients.Conclusions  Local hyperthermia enhances the systemic absorption of MMC during intravesical chemotherapy for bladder cancer. In the doses used, plasma MMC concentrations were always more than six times lower than those shown to cause toxicity.

1 August 1997 in Journal of Periodontology
Verified
Journal Article
Closed access
PDF file
GGGiovanna Giuliana
Giovanna Giuliana
Giuseppe PizzoGiuseppe Pizzo
Giuseppe Pizzo
MMMaria E. Milici
Maria E. Milici
GMGiuliana C. Musotto
Giuliana C. Musotto
RGRosalia Giangreco
Rosalia Giangreco
The purpose of this study was to investigate the in vitro antifungal properties of seven commercial mouthrinses containing antimicrobial agents. These included cetylpyridinium chloride (CPC), chlorhexidine digluconate (CHX), hexetidine (HEX), sanguinarine (SNG), and triclosan (TRN). The minimum fungicidal concentration (MFC) against six species of yeasts was determined by a broth macrodilution method. The kill‐time of mouthrinses at half the concentration of the commercial formulations was also determined. MFCs were achieved with each mouthrinse, except the SNG‐containing mouthrinse; against all the organisms being tested. However, the CPC‐containing mouthrinse appeared more active than the other products (P < 0.001). There were no significant differences in MFC values among CHX mouthrinse products, once adjusted for initial concentration differences (P = 0.1). Kill‐times of mouthrinses containing either CHX or CPC were less than or equal to 180 seconds with all the species of yeasts, and no significant differences were found among these products (P = 0.18). On the other hand, mouthrinses containing either TRN or HEX did not show a lethal effect on Candida albicans, Candida parapsilosis, or Candida guilliermondii. No kill‐times were achieved with the SNG‐containing mouthrinse. These results suggest that mouthrinses containing antimicrobial agents might represent an appropriate alternative to conventional antifungal drugs in the management of oral candidiasis. However, the effectiveness of antimicrobial mouthrinses as antifungal agents needs to be evaluated in further clinical trials. J Periodontol 1997;68:729–733.

29 March 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
FFFolli Franco
Folli Franco
VGValeria Guzzi
Valeria Guzzi
LPLucia Perego
Lucia Perego
Dawn K. ColettaDawn K. Coletta
Dawn K. Coletta
GFGiovanna Finzi
Giovanna Finzi
Paolo FiorinaPaolo Fiorina
Paolo Fiorina
In type 1 diabetes (T1D) vascular complications such as accelerated atherosclerosis and diffused macro-/microangiopathy are linked to chronic hyperglycemia with a mechanism that is not yet well understood. End-stage renal disease (ESRD) worsens most diabetic complications, particularly, the risk of morbidity and mortality from cardiovascular disease is increased several fold. We evaluated protein regulation and expression in skin biopsies obtained from T1D patients with and without ESRD, to identify pathways of persistent cellular changes linked to diabetic vascular disease. We therefore examined pathways that may be normalized by restoration of normoglycemia with kidney-pancreas (KP) transplantation. Using proteomic and ultrastructural approaches, multiple alterations in the expression of proteins involved in oxidative stress (catalase, superoxide dismutase 1, Hsp27, Hsp60, ATP synthase δ chain, and flavin reductase), aerobic and anaerobic glycolysis (ACBP, pyruvate kinase muscle isozyme, and phosphoglycerate kinase 1), and intracellular signaling (stratifin-14-3-3, S100-calcyclin, cathepsin, and PPI rotamase) as well as endothelial vascular abnormalities were identified in T1D and T1D+ESRD patients. These abnormalities were reversed after KP transplant. Increased plasma levels of malondialdehyde were observed in T1D and T1D+ESRD patients, confirming increased oxidative stress which was normalized after KP transplant. Our data suggests persistent cellular changes of anti-oxidative machinery and of aerobic/anaerobic glycolysis are present in T1D and T1D+ESRD patients, and these abnormalities may play a key role in the pathogenesis of hyperglycemia-related vascular complications. Restoration of normoglycemia and removal of uremia with KP transplant can correct these abnormalities. Some of these identified pathways may become potential therapeutic targets for a new generation of drugs.